Compare ARK Genomic Revolution ETF (ARKG) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs BridgeBio Pharma Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.36, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BBIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $90.17 |
52-Week Low | $24.02 | $47.29 |
Market Cap | — | $16.36B |
Enterprise Value | — | $18.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
